Royal College of Surgeons in Ireland
Browse

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.

Download (18.99 MB)
Version 3 2022-11-29, 10:39
Version 2 2022-02-02, 11:25
Version 1 2019-11-22, 17:06
journal contribution
posted on 2022-11-29, 10:39 authored by Manuela Salvucci, Maximilian L. Würstle, Clare Morgan, Sarah Curry, Mattia Cremona, Andreas Ulrich Lindner, Orna Bacon, Alexa J. Resler, Áine C. Murphy, Robert O'Byrne, Lorna Flanagan, Sonali Dasgupta, Nadege Rice, Camilla Pilati, Elisabeth Zink, Lisa M. Schöller, Sinead ToomeySinead Toomey, Mark Lawler, Patrick G. Johnston, Richard Wilson, Sophie Camilleri-Broët, Manuel Salto-Tellez, Deborah McNamaraDeborah McNamara, Elaine KayElaine Kay, Pierre Laurent-Puig, Sandra Van Schaeybroeck, Bryan HennessyBryan Hennessy, Daniel b. Longley, Markus RehmMarkus Rehm, Jochen PrehnJochen Prehn

Purpose: Apoptosis is essential for chemotherapy responses. In this discovery and validation study, we evaluated the suitability of a mathematical model of apoptosis execution (APOPTO-CELL) as a stand-alone signature and as a constituent of further refined prognostic stratification tools.Experimental Design: Apoptosis competency of primary tumor samples from patients with stage III colorectal cancer (n = 120) was calculated by APOPTO-CELL from measured protein concentrations of Procaspase-3, Procaspase-9, SMAC, and XIAP. An enriched APOPTO-CELL signature (APOPTO-CELL-PC3) was synthesized to capture apoptosome-independent effects of Caspase-3. Furthermore, a machine learning Random Forest approach was applied to APOPTO-CELL-PC3 and available molecular and clinicopathologic data to identify a further enhanced signature. Association of the signature with prognosis was evaluated in an independent colon adenocarcinoma cohort (TCGA COAD, n = 136).Results: We identified 3 prognostic biomarkers (P = 0.04, P = 0.006, and P = 0.0004 for APOPTO-CELL, APOPTO-CELL-PC3, and Random Forest signatures, respectively) with increasing stratification accuracy for patients with stage III colorectal cancer.The APOPTO-CELL-PC3 signature ranked highest among all features. The prognostic value of the signatures was independently validated in stage III TCGA COAD patients (P = 0.01, P = 0.04, and P = 0.02 for APOPTO-CELL, APOPTO-CELL-PC3, and Random Forest signatures, respectively). The signatures provided further stratification for patients with CMS1-3 molecular subtype.Conclusions: The integration of a systems-biology-based biomarker for apoptosis competency with machine learning approaches is an appealing and innovative strategy toward refined patient stratification. The prognostic value of apoptosis competency is independent of other available clinicopathologic and molecular factors, with tangible potential of being introduced in the clinical management of patients with stage III colorectal cancer. Clin Cancer Res; 23(5); 1200-12. ©2016 AACR.

Funding

European Union Framework Programme 7. Science Foundation Ireland. Irish Cancer Society. Heath Research Board. ERASMUS.

History

Comments

The original article is available at http://clincancerres.aacrjournals.org

Published Citation

Salvucci M, Würstle ML, Morgan C, Curry S, Cremona M, Lindner AU, Bacon O, Resler AJ, Murphy ÁC, O'Byrne R, Flanagan L, Dasgupta S, Rice N, Pilati C, Zink E, Schöller LM , Toomey S, Lawler M, Johnston PG, Wilson R, Camilleri-Broët S, Salto-Tellez M, McNamara DA, Kay EW, Laurent-Puig P, Van Schaeybroeck S, Hennessy BT, Longley DB, Rehm M, Prehn JH. A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. Clinical Cancer Research. 2017;23(5):1200-1212.

Publication Date

2017-03-01

PubMed ID

27649552

Department/Unit

  • Beaumont Hospital
  • Centre for Systems Medicine
  • Pathology
  • Physiology and Medical Physics
  • Surgery